Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Helsingborg – page 9

1 322 clinical trials in Helsingborg, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Helsingborg at a glance
1 322
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 322 trials in Helsingborg

Open in trial search

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Neuroblastoma

Recruiting

Study of hu14.18K322A with temozolomide and irinotecan in children and adolescents with high‑risk neuroblastoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:hu14.18K322A
  • Sponsor:Renaissance Pharma Limited

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Study of Short‑and Long‑Term Hemodynamic and Physiological Effects of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Region Skane

Phase IIb Open‑Label Study of Intrathecal Melpida (AAV9/AP4M1) in Patients with Hereditary Spastic Paraplegia Type 50 (SPG50)

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Melpida
  • Sponsor:Elpida Therapeutics SPC

Osteoarthritis

Recruiting

Efficacy and Safety of LTG-321 Compared with Placebo in Patients with Osteoarthritis of the Knee

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:LTG-321
  • Sponsor:Latigo Biotherapeutics Inc.

Long‑Term Monitoring of Malignancy Risk in Early‑Onset Metachromatic Leukodystrophy Patients Treated with atidarsagene autotemcel

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Helsingborg

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies exploring treatments for heart failure and cardiovascular conditions, including research on combination therapies to reduce cardiovascular mortality.

  • Heart Failure Prevention
  • Atrial Fibrillation
  • Takotsubo Syndrome

Groundbreaking trials evaluating novel drug combinations and therapeutic approaches for cardiac conditions.

02 Oncology Studies

Advanced research focusing on multiple myeloma treatment, particularly for patients with relapsed or refractory conditions.

  • Blood Cancer Therapies
  • Combination Treatment Approaches
  • Bladder Cancer Management

Evaluating innovative therapeutic combinations and comparing effectiveness of different treatment regimens.

03 Infectious Diseases

Clinical investigations into treatments for various infections, including bacterial infections and antibiotic resistance.

  • Staphylococcus Aureus Treatment
  • Urinary Tract Infections
  • Viral Lung Infections

Studies focusing on alternative antibiotics and novel approaches to combat resistant infections.

04 Mental Health Research

Studies examining innovative treatments for psychiatric disorders, including treatment-resistant conditions.

  • Schizophrenia Spectrum Disorders
  • Treatment-Resistant Depression
  • Novel Therapeutic Approaches

Investigating immunomodulatory treatments and new compounds for mental health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.